News

The FDA in its complete response letter issued to the company conveyed that the new drug application (NDA) for dasotraline could not be approved in its current form.

The original contract in Alzheimer’s disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May

The Phase 2 study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb

Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase

KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor

The new facility, which will serve as the flagship location for ICS, will further strengthen the company’s already robust end-to-end, integrated solutions for improving access to specialty medication,

Adapt Pharma is a privately-held company committed to expanding affordable access to Narcan (naloxone HCI) nasal spray and to progressing treatment options in the field of addiction. The

Onvansertib is a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. Trovagene executive chairman Dr Thomas Adams said: “The European Commission’s decision to grant orphan

The study results, as well as the results of Sonoma’s previous HOCl acne studies (total of 127 patients), were presented by the principal investigator, Mark Steven Nestor, M.D.,